prikaz prve stranice dokumenta Antieritrocitna protutijela u transfundiranih bolesnika s mijelodisplastičnim sindromom
  Download
PDF 1.19 MB
master's thesis
Antieritrocitna protutijela u transfundiranih bolesnika s mijelodisplastičnim sindromom
Osijek: Josip Juraj Strossmayer University of Osijek, Faculty of Medicine Osijek, 2020. urn:nbn:hr:152:649691
Leskovar, Ivana
Josip Juraj Strossmayer University of Osijek
Faculty of Medicine Osijek

Institutional repository: Repository of the Faculty of Medicine Osijek

Cite this document

Leskovar, I. (2020). Antieritrocitna protutijela u transfundiranih bolesnika s mijelodisplastičnim sindromom (Master's thesis). Osijek: Josip Juraj Strossmayer University of Osijek, Faculty of Medicine Osijek. Retrieved from https://urn.nsk.hr/urn:nbn:hr:152:649691

Leskovar, Ivana. "Antieritrocitna protutijela u transfundiranih bolesnika s mijelodisplastičnim sindromom." Master's thesis, Josip Juraj Strossmayer University of Osijek, Faculty of Medicine Osijek, 2020. https://urn.nsk.hr/urn:nbn:hr:152:649691

Leskovar, Ivana. "Antieritrocitna protutijela u transfundiranih bolesnika s mijelodisplastičnim sindromom." Master's thesis, Josip Juraj Strossmayer University of Osijek, Faculty of Medicine Osijek, 2020. https://urn.nsk.hr/urn:nbn:hr:152:649691

Leskovar, I. (2020). 'Antieritrocitna protutijela u transfundiranih bolesnika s mijelodisplastičnim sindromom', Master's thesis, Josip Juraj Strossmayer University of Osijek, Faculty of Medicine Osijek, accessed 26 December 2024, https://urn.nsk.hr/urn:nbn:hr:152:649691

Leskovar I. Antieritrocitna protutijela u transfundiranih bolesnika s mijelodisplastičnim sindromom [Master's thesis]. Osijek: Josip Juraj Strossmayer University of Osijek, Faculty of Medicine Osijek; 2020 [cited 2024 December 26] Available at: https://urn.nsk.hr/urn:nbn:hr:152:649691

I. Leskovar, "Antieritrocitna protutijela u transfundiranih bolesnika s mijelodisplastičnim sindromom", Master's thesis, Josip Juraj Strossmayer University of Osijek, Faculty of Medicine Osijek, Osijek, 2020. Available at: https://urn.nsk.hr/urn:nbn:hr:152:649691

Metadata
TitleAntieritrocitna protutijela u transfundiranih bolesnika s mijelodisplastičnim sindromom
Title (english)Red cell antibodies in transfused patients with myelodysplastic syndrome
AuthorIvana Leskovar
MentorSilva Zupančić-Šalek (mentor)
Committee memberMarina Samardžija (predsjednik povjerenstva)
Committee memberSaška Marczi (član povjerenstva)
Committee memberSilva Zupančić-Šalek (član povjerenstva)
GranterJosip Juraj Strossmayer University of Osijek
Faculty of Medicine Osijek
Osijek
Defense date and country2020-09-25, Croatia
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Abstract
Cilj istraživanja: Ciljevi ovog istraživanja su ispitati učestalost antieritrocitnih protutijela u transfundiranoj skupini bolesnika s mijelodisplatičnim sindromom (MDS), istražiti specifičnost antieritrocitnih protutijela i njihov udio u imuniziranoj skupini bolesnika, ispitati postoje li razlike u intenzitetu transfuzijskog liječenja u bolesnika koji su razvili protutijela u odnosu na one koji nisu imunizirani i ispitati javljaju li se autoprotijela češće u skupini aloimuniziranih bolesnika u odnosu na skupinu koja nije razvila aloprotutijela. Ustroj studije: Ovo je presječna studija s povijesnim podatcima. Ispitanici i metode: Za potrebe istraživanja pretražene su informatičke baze podataka KBC-a Zagreb i prikupljeni demografski podatci o bolesnicima, imunohematološkom ispitivanju i transfuzijskom liječenju. Rezultati: U istraživanju je sudjelovalo 112 transfundiranih bolesnika s MDS-om. Značajno više (70%) bolesnika nije razvio antieritrocitna protutijela. Tridestčetiri (30%) bolesnika je razvilo antieritrocitna protutijela: 27 (24%) alo, 13 (12%) auto od kojih je 6 razvilo i auto i alo protutijelo. Jedno aloprotutijelo razvilo je 52%, dva 19%, a tri 30% bolesnika. Od otkrivenih protutijela 62% su bila iz Rh sustava, 13% iz Kell sustava, 13% iz Kidd sustava, 4% iz Lewis sustava, a po 2% iz Lutheran i Yt sustava. Broj transfundiranih doza koncentrata eritrocita značajno je veći kod bolesnika koji su razvili protutijela naspram onih koji nisu. Zaključak: Veliki broj bolesnika tijekom liječenja MDS-a razvije antieritrocitna protutijela. Bolesnici s razvijenim auto i aloprotutijelima češće se liječe transfuzijama koncentrata eritrocita nego neimunizirani bolesnici.
Abstract (english)
Aim: The aim of this studyis to test the frequency of RBC antibodies in a group of transfused patients with myelodysplastic syndrome (MDS), analyze the specificity of RBC antibodies and proportion of immunized patients they affect, find differences in the intensity of transfusion therapy in patients who developed antibodies as opposed to non-immunized patients, and investigate whether autoantibodies were more frequent in the alloimmunized or non-alloimmunized group of patients. Study design: This is a cross-sectional study with historical data. Patients and methods: Computer databases of University Hospital Center Zagreb were searched and demographic data on patients, results of immunohematology testing and details of transfusion therapy were collected. Results: The study included 112 transfused patients with MDS. More patients (70%)did not develop antibodies. A total of 34 (30%) patients developed RBC antibodies: 27 (24%) allo-, 13 (12%) auto-, 6of which had both auto-andallo-antibodies. Concerning antibodies, 52% patients developed one, 19% developed two and 30% developed three. Rh (62%) system antibodies were the most frequent, followed by Kell (13%), Kidd (13%), Lewis (4%) , Lutheran (2%) and Yt (2%) systems. Number of RBC transfusion was much higher in patients who developed antibodies. Conclusion: Many patients with MDS develop RBC antibodies that complicate treatment. Patients with developed auto- and alloantibodies receive RBC concentrate transfusions more frequently than non-immunized patients.
Keywords
Keywords (english)
Languagecroatian
URN:NBNurn:nbn:hr:152:649691
Study programmeTitle: University graduate study
Study programme type: university
Study level: graduate
Academic / professional title: magistar/magistra medicinsko laboratorijske dijagnostike (magistar/magistra medicinsko laboratorijske dijagnostike)
Type of resourceText
File originBorn digital
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2022-10-14 08:25:33